Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

Spread This NewsCity Press Globally, people wanting to lose weight are turning to Ozempic, the so-called miracle drug ...

The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.

Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec.

(HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...

1 Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China 2 Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, ...